Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

70 results about "Inflammatory infiltration" patented technology

Pharmaceutical composition for treating Hashimoto's thyroiditis and preparation method thereof

The invention relates to a pharmaceutical composition for treating Hashimoto's thyroiditis and a preparation method thereof. The pharmaceutical composition is composed of bupleurum, radix curcumae, prunella vulgaris, rhizoma Dioscoreae Nipponicae, thunberg fritillary bulb, radix scrophulariae, edible tulip, astragalus, dark plum and other components, and can be made into granules, capsules, tablets or pills by the conventional pharmaceutical processes. The pharmaceutical composition has the effects of soothing liver-qi stagnation, reducing phlegm, removing stasis, and softening hardness to dissipate stagnation, and applies to patients with Hashimoto's thyroiditis and thyroid nodules. Clinical studies have shown that the pharmaceutical composition can significantly improve the symptoms of Hashimoto's thyroiditis, reduce the thyroid volume and isthmus thickness, and reduce the level of TgAb and TPOAb, and the total effective rate is 97.22%. In addition, for patients with thyroid nodules, nodules can be significantly reduced or even disappeare, no significant adverse reactions are presented in the course of treatment. Experimental studies have shown that the pharmaceutical composition reduces the level of TgAb and TPOAb, and reduces inflammatory infiltration and thyroid follicular damage.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Medicine for treating rheumatoid arthritis and uses thereof

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is muscone, and the effective concentration is 10-1000 [mu]M. Muscone is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As proved by animal experiments, that muscone can reduce joint injury and inflammatory infiltration area, bone mass defect and cartilage defect of the collagen-induced rheumatoid arthritis mice, and alleviate ankle arthritis injury. The muscone of the invention can improve the symptoms of rheumatoid arthritis. The invention also discloses the use of muscone in preparing medicines or health products for preventing and treating rheumatoid arthritis. The effective concentration of muscone is 10-1000 [mu]M.
Owner:LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE

A kind of pharmaceutical composition for treating alcoholic liver injury

The invention relates to a medicinal composition for treating alcoholic liver injury. The medicinal composition contains Japanese ginseng total saponins and Japanese ginseng polysaccharides serving as active ingredients and a pharmaceutically acceptable carrier. Due to the adoption of a Japanese ginseng total saponin-polysaccharide composition, certain phenomena can be overcome remarkably, the liver function indexes can be lowered very remarkably, MDA (Methylene Dioxyamphetamine) in liver tissues is reduced, SOD (Superoxide Dismutase) and GSH-Px activity are enhanced, and the inflammatory infiltration and fat vacuoles of liver tissues are reduced.
Owner:CHINA THREE GORGES UNIV

Application of ALDH3A1/IL-17 axis in preparation of medicine for treating refractory ulcer

The invention relates to application of an ALDH3A1 / IL-17 axis in preparation of a medicine for treating refractory ulcer. According to the invention, proteomics is combined with biological information analysis, and experimental verification is combined for use, so the protein expression of ALDH3A1 in a wound surface of a db / db diabetic mouse is reduced; and by overexpressing ALDH3A1 expression in HaCaT cells, proliferation of the cells is increased, inflammatory infiltration is relieved, and an IL-17 pathway is remarkably inhibited. It is prompted in the invention that ALDH3A1 can improve chronic inflammation, promote cell proliferation and heal wounds by inhibiting downstream IL-17 signal channels, and the targeted ALDH3A1 / IL-17 axis can be used as a novel treatment method and is used for treating refractory ulcers, chronic inflammation after injury, infection and other types of wounds in the future.
Owner:SHANGHAI DERMATOLOGY HOSPITAL

New uses of Ajuga ciliata Bunge extract

The present invention relates to new uses of an Ajuga ciliata Bunge extract, particularly to applications of the Ajuga ciliata Bunge extract in preparation of drugs for prevention and treatment of gynecological inflammatory diseases. According to the present invention, experimental results show that the gynecological inflammation treatment effects of the Ajuga ciliata Bunge extract on the two chronic pelvic inflammatory disease rat models caused by escherichia coli and phenol paste are verified, wherein the change of the blood rheology, the inflammatory factors and other indicators of the chronic pelvic inflammatory disease rat model caused by the phenol paste are observed after using the Ajuga ciliata Bunge extract, the change of the immunology indicator of the chronic pelvic inflammatory disease rat model caused by the escherichia coli is observed after using the Ajuga ciliata Bunge extract, and the intervention effects of the Ajuga ciliata Bunge extract on the uterus tissue inflammatory infiltration caused by chronic inflammations, tissue adhesion, and inflammatory mass caused by attachment hyperblastosis and the like are observed, such that the Ajuga ciliata Bunge extract provides the treatment effects on the long-term chronic inflammations and the attachment hyperblastosis caused by the long-term chronic inflammations.
Owner:BEIJING KONRUNS PHARM CO LTD

Triptolide autolytic microneedle

The invention discloses a triptolide autolytic microneedle. A prescription of a needle tip matrix of the triptolide autolytic microneedle comprises the following components of, in parts by weight, 24-29 parts of PVP (Polyvinyl Pyrrolidone), 7.8-8.3 parts of PVA (Polyvinyl Alcohol), 0.45-0.65 part of CMC-Na (Sodium Carboxymethyl Cellulose), 0.28-0.42 part of triptolide, 40-45 parts of distilled water and 20-23 parts of absolute ethyl alcohol; and a prescription of a backing layer matrix of the triptolide autolytic microneedle comprises the following components of, in parts by weight, 32-37 parts of PVP (Polyvinyl Pyrrolidone), 9-12 parts of PVA (Polyvinyl Alcohol) and 53-58 parts of distilled water. The microneedle has good microneedle formability and mechanical strength, an RSD value of a medicine loading capacity is 0.98%, a process is stable and feasible, a needle tip of a medicine-loading microneedle enables most of medicines to rapidly reach a body to take effect rapidly, and the medicine use safety of the triptolide can be improved due to a slow-release effect of a microneedle matrix; and by reducing inflammatory infiltration of cells in a synovial membrane, the expression of inflammatory factors such as TNF-alpha, IL-17, PGE2, IgG, IgM and IgA can be reduced, the expression of OPG can be increased, the expression of RANKL and an RANKL / OPG ratio can be reduced, and rheumatoid arthritis can be treated.
Owner:GUIZHOU YANGSHENG MEDICAL INSTR

A kind of pharmaceutical composition for treating Hashimoto's thyroiditis and preparation method thereof

The invention relates to a pharmaceutical composition for treating Hashimoto's thyroiditis and a preparation method thereof. The pharmaceutical composition is composed of bupleurum, radix curcumae, prunella vulgaris, rhizoma Dioscoreae Nipponicae, thunberg fritillary bulb, radix scrophulariae, edible tulip, astragalus, dark plum and other components, and can be made into granules, capsules, tablets or pills by the conventional pharmaceutical processes. The pharmaceutical composition has the effects of soothing liver-qi stagnation, reducing phlegm, removing stasis, and softening hardness to dissipate stagnation, and applies to patients with Hashimoto's thyroiditis and thyroid nodules. Clinical studies have shown that the pharmaceutical composition can significantly improve the symptoms of Hashimoto's thyroiditis, reduce the thyroid volume and isthmus thickness, and reduce the level of TgAb and TPOAb, and the total effective rate is 97.22%. In addition, for patients with thyroid nodules, nodules can be significantly reduced or even disappeare, no significant adverse reactions are presented in the course of treatment. Experimental studies have shown that the pharmaceutical composition reduces the level of TgAb and TPOAb, and reduces inflammatory infiltration and thyroid follicular damage.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Applications of total cyclopentene iridoid glycoside of Hedyotis diffusa Willd in preparation of acute kidney injury prevention and treatment drugs

The invention relates to applications of the total cyclopentene iridoid glycoside of Hedyotis diffusa Willd in preparation of acute kidney injury prevention and treatment drugs. According to the present invention, in the applications, with the drugs, the inflammatory infiltration of renal tissue can be significantly reduced, the amount of TNF-alpha, IL-1beta, IL-6 and MCP-1 can be effectively inhibited, and the kidney injury prevention and treatment effects are remarkable.
Owner:广州南方医大科技园有限公司

Application of SNase in preparation of medicament for treating inflammatory bowel disease

ActiveCN109608526ARelieves Colon Inflammation in Inflammatory Bowel DiseaseAvoid degradationPeptide/protein ingredientsDigestive systemFecesIntestinal inflammation
The invention relates to the application of staphylococcal nuclease (SNase) in preparation of a medicament for preventing or treating inflammatory bowel disease. The object of the present invention isto provide a novel use of SNase in action of resisting inflammatory bowel disease. Results show that SNase can significantly alleviate colonic inflammation in C57BL / 6J mice, can better control the body weight, colon length, fecal occult blood and inflammatory infiltration of the C57BL / 6J mice, and significantly improve the survival rate of the C57BL / 6J mice. Therefore, the SNase can significantlyalleviate intestinal inflammation in the C57BL / 6J mice, and can be used for development of medicaments for prevention and treatment of inflammatory bowel diseases.
Owner:CHINA PHARM UNIV

Chinese herbal medicine composition with effects of diminishing inflammation and relieving itching and preparation method of Chinese herbal medicine composition

The invention discloses a Chinese herbal medicine composition with effects of diminishing inflammation and relieving itching. The Chinese herbal medicine composition comprises the following components in parts by mass: 55-65 parts of fructus cnidii, 15-25 parts of realgar, 25-35 parts of rheum officinale, 10-20 parts of borneol, 1-2 parts of dragon's blood, 10-20 parts of red flower, 10-20 parts of Red Paeony Root, 5-15 parts of Ligusticum wallichii, 25-35 parts of pawpaw, 5-15 parts of Angelica sinensis, 5-15 parts of Coptis chinensis, 5-15 parts of cortex moutan, 10-20 parts of the seed of cowherb, 10-20 parts of selfheal and 15-25 parts of honeysuckle. The invention also discloses a method for preparing the Chinese herbal medicine composition with effects of diminishing inflammation and relieving itching. The Chinese herbal medicine composition disclosed by the invention has the effects of killing parasites to relieve itching, inducing diuresis to remove turbidity, clearing away heat and toxic materials, promoting blood circulation and expelling wind, inhibiting release of inflammatory factors and alleviating inflammatory infiltration, and good effects of diminishing inflammation and relieving itching are achieved.
Owner:苏珊珊

Application of total flavonoids of rosa roxburghii

The invention discloses an application of total flavonoids of rosa roxburghii in preparation of drugs, health-care products and health-care food for preventing and treating alcoholic liver disease. Provided are drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 3-99% of the total flavonoids extract of rosa roxburghii, and the total flavonoids extract of rosa roxburghii are used as an active ingredient. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.08-1% of the total flavonoids of rosa roxburghii. Through implementation of a most recognized model of alcoholic liver disease in mice, the total flavonoids of rosa roxburghii are found out to obviously alleviate the liver pathological changes induced by alcohol; liver enlargement, weight gain, fat accumulation and inflammatory infiltration degree are significantlyimproved; biochemical and pathological indicators are decreased greatly. Therefore, the total flavonoids of rosa roxburghii can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination and are used for developing corresponding drugs, health-care products or health-care food.
Owner:阎永平

Application of rosa roxburghii aqueous extracts

The invention discloses an application of various rosa roxburghii aqueous extracts in preparation of drugs, health-care products and health-care food for preventing and/or treating alcoholic liver disease. Provided are drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 20-99% of the rosa roxburghii aqueous extracts. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.5-33% of the rosa roxburghii aqueous extracts; the invention also provides a blended alcoholic drinks comprising 0.5-7% of the rosa roxburghii aqueous extracts; the invention also provides fruit-flavored beer drinks comprising 0.5-4% of the rosa roxburghiiaqueous extracts; the invention also provides additive grape wine comprising 0.5-2% of the rosa roxburghii aqueous extracts; the invention also provides blended grape wine drinks comprising 0.5-2% ofthe rosa roxburghii aqueous extracts. Through implementation of the most recognized model of alcoholic liver disease in mice, the rosa roxburghii aqueous extracts with various concentrations are found out to alleviate the liver pathological changes induced by alcohol in different extents; liver enlargement, weight gain, fat accumulation and inflammatory infiltration degree are significantly improved; biochemical and pathological indicators are significantly reduced. The rosa roxburghii aqueous extracts can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination, and is used for developing corresponding drugs, health-care products or health-care food.
Owner:阎永平

Il20-rb-specific antibodies and uses thereof for treating acute aggregation of

Chronic obstructive pulmonary disease (COPD) is still the major cause of global morbidity and mortality. A COPD acute exacerbation patient (AE-COPD) is mainly caused by respiratory tract infection and is related to inevitable decline of lung function, edema exacerbation and airway and systemic inflammation. Previous results show that treatment with an anti-IL-20Rb blocking antibody increases bacterial clearance in control mice infected with Streptococcus pneumoniae and protects CS exposed mice from bacterial infection by reducing bacterial load and inflammatory infiltration. Therefore, people are of interest in the production of monoclonal antibodies specific for IL-20Rb with neutralizing activity for AE-COPD treatment. This need is met by providing an antibody that is specific for IL-20Rb.
Owner:INSERM法国国家健康医学研究院 +5
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products